202 related articles for article (PubMed ID: 33257682)
1. ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Constantin D; Widmann C
Cell Death Dis; 2020 Nov; 11(11):1019. PubMed ID: 33257682
[TBL] [Abstract][Full Text] [Related]
2. Correction to: ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Constantin D; Widmann C
Cell Death Dis; 2021 Jan; 12(1):96. PubMed ID: 33462186
[No Abstract] [Full Text] [Related]
3. Growth differentiation factor 15 (GDF-15) plasma levels increase during bleomycin- and cisplatin-based treatment of testicular cancer patients and relate to endothelial damage.
Altena R; Fehrmann RS; Boer H; de Vries EG; Meijer C; Gietema JA
PLoS One; 2015; 10(1):e0115372. PubMed ID: 25590623
[TBL] [Abstract][Full Text] [Related]
4. ASH2L is involved in promotion of endometrial cancer progression via upregulation of PAX2 transcription.
Zeng K; Wu Y; Wang C; Wang S; Sun H; Zou R; Sun G; Song H; Liu W; Sun N; Wei S; Liu W; Su Y; Zhou T; Zhang Y; Zhao Y
Cancer Sci; 2020 Jun; 111(6):2062-2077. PubMed ID: 32279431
[TBL] [Abstract][Full Text] [Related]
5. Bleomycin, a review.
Crooke ST; Bradner WT
J Med; 1976; 7(5):333-428. PubMed ID: 64579
[No Abstract] [Full Text] [Related]
6. A review of the bleomycin experience in the United States.
Friedman MA
Recent Results Cancer Res; 1978; 63():152-68. PubMed ID: 81499
[TBL] [Abstract][Full Text] [Related]
7. Low expression of ASH2L protein correlates with a favorable outcome in acute myeloid leukemia.
Butler JS; Qiu YH; Zhang N; Yoo SY; Coombes KR; Dent SY; Kornblau SM
Leuk Lymphoma; 2017 May; 58(5):1207-1218. PubMed ID: 28185526
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.
Ozyerli-Goknar E; Kala EY; Aksu AC; Bulut I; Cingöz A; Nizamuddin S; Biniossek M; Seker-Polat F; Morova T; Aztekin C; Kung SHY; Syed H; Tuncbag N; Gönen M; Philpott M; Cribbs AP; Acilan C; Lack NA; Onder TT; Timmers HTM; Bagci-Onder T
Cell Commun Signal; 2023 Nov; 21(1):328. PubMed ID: 37974198
[TBL] [Abstract][Full Text] [Related]
9. To dive or not to dive with bleomycin: a practical algorithm.
van Hulst RA; Rietbroek RC; Gaastra MT; Schlösser NJ
Aviat Space Environ Med; 2011 Aug; 82(8):814-8. PubMed ID: 21853861
[TBL] [Abstract][Full Text] [Related]
10. Expression specificity and compensation effect of Ash2l-1/Ash2l-2 in mouse embryonic stem cells.
Xie J; Fan C; Zhang JL; Zhang SQ
Yi Chuan; 2018 Mar; 40(3):237-249. PubMed ID: 29576547
[TBL] [Abstract][Full Text] [Related]
11. Controlled studies with bleomycin in solid tumors and lymphomas.
Bonadonna G; Tancini G; Bajetta E
Prog Biochem Pharmacol; 1976; 11():172-84. PubMed ID: 63961
[No Abstract] [Full Text] [Related]
12. Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers.
den Hollander MW; Westerink ND; Lubberts S; Bongaerts AH; Wolf RF; Altena R; Nuver J; Oosting SF; de Vries EG; Walenkamp AM; Meijer C; Gietema JA
Oncologist; 2016 Aug; 21(8):995-1001. PubMed ID: 27328932
[TBL] [Abstract][Full Text] [Related]
13. Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth.
Shah KK; Whitaker RH; Busby T; Hu J; Shi B; Wang Z; Zang C; Placzek WJ; Jiang H
Exp Cell Res; 2019 Sep; 382(2):111485. PubMed ID: 31251903
[TBL] [Abstract][Full Text] [Related]
14. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
15. Current status of American studies with bleomycin.
Carter SK; Blum RH
Prog Biochem Pharmacol; 1976; 11():158-71. PubMed ID: 63960
[No Abstract] [Full Text] [Related]
16. Effects of curcumin on bleomycin‑induced oxidative stress in malignant testicular germ cell tumors.
Cort A; Ozdemir E; Timur M; Ozben T
Mol Med Rep; 2012 Oct; 6(4):860-6. PubMed ID: 22825355
[TBL] [Abstract][Full Text] [Related]
17. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
18. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma.
Peckham MJ; Horwich A; Blackmore C; Hendry WF
Cancer Treat Rep; 1985 May; 69(5):483-8. PubMed ID: 2408750
[TBL] [Abstract][Full Text] [Related]
19. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
20. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro.
Nuver J; De Haas EC; Van Zweeden M; Gietema JA; Meijer C
Oncol Rep; 2010 Jan; 23(1):247-53. PubMed ID: 19956889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
